Financial reports
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
8 Mar 22
10-Q
2021 Q3
Quarterly report
3 Nov 21
Current reports
8-K
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Mar 24
8-K
Other Events
22 Mar 24
8-K
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZETĀ® Product Line in U.S. and Canada
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
8-K
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
13 Nov 23
8-K
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
7 Nov 23
8-K
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial
7 Sep 23
8-K
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
9 Aug 23
8-K
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
21 Jul 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
10 Aug 23
424B5
Prospectus supplement for primary offering
21 Jul 23
424B5
Prospectus supplement for primary offering
7 Feb 23
S-8
Registration of securities for employees
5 Aug 22
S-3
Shelf registration
30 Jul 21
424B5
Prospectus supplement for primary offering
5 Feb 21
424B5
Prospectus supplement for primary offering
4 Feb 21
S-8
Registration of securities for employees
4 Aug 20
424B5
Prospectus supplement for primary offering
21 Jun 19
424B2
Prospectus for primary offering
10 Oct 18
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Oct 22
DEF 14A
Definitive proxy
7 Oct 22
PRE 14A
Preliminary proxy
27 Sep 22
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
Other
CT ORDER
Confidential treatment order
4 Nov 21
EFFECT
Notice of effectiveness
17 Aug 21
CORRESP
Correspondence with SEC
12 Aug 21
UPLOAD
Letter from SEC
5 Aug 21
CT ORDER
Confidential treatment order
11 Dec 18
EFFECT
Notice of effectiveness
10 Oct 18
CORRESP
Correspondence with SEC
5 Oct 18
CORRESP
Correspondence with SEC
28 Sep 18
UPLOAD
Letter from SEC
21 Sep 18
CORRESP
Correspondence with SEC
12 Sep 18
Ownership
SC 13G
INGALLS & SNYDER LLC
27 Mar 24
SC 13G
ASEN R SCOTT
16 Feb 24
SC 13G/A
Lion Point Capital, LP
14 Feb 24
SC 13G/A
Bleichroeder LP
1 Dec 23
4
Judith J. Robertson
23 Jun 23
4
Gail J Maderis
23 Jun 23
4
PETER S GARCIA
23 Jun 23
4
Gail M Farfel
23 Jun 23
4
Terrence F Blaschke
23 Jun 23
4
MOHAMMAD AZAB
23 Jun 23